1 Cherry, J. D. Treatment of Pertussis-2017. Journal of the Pediatric Infectious Diseases Society, doi:10.1093/jpids/pix044 (2017).
2 Mattoo, S. & Cherry, J. D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clinical microbiology reviews 18, 326-382, doi:10.1128/cmr.18.2.326-382.2005 (2005).
3 Tan, T., Trindade, E. & Skowronski, D. Epidemiology of pertussis. The Pediatric infectious disease journal 24, S10-18 (2005).
4 Burdin, N., Handy, L. K. & Plotkin, S. A. What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines. Cold Spring Harbor perspectives in biology 9, doi:10.1101/cshperspect.a029454 (2017).
5 Gu, X. X. et al. Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases. Clinical and vaccine immunology : CVI 24, doi:10.1128/cvi.00034-17 (2017).
6 Le, T. et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis 190, 535-544, doi:10.1086/422035 (2004).
7 Heininger, U., Cherry, J. D. & Stehr, K. Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis 38, 591-594, doi:10.1086/381439 (2004).
8 Fouda, G. G., Martinez, D. R., Swamy, G. K. & Permar, S. R. The Impact of IgG transplacental transfer on early life immunity. Immunohorizons 2, 14-25, doi:10.4049/immunohorizons.1700057 (2018).
9 Skoff, T. H., Baumbach, J. & Cieslak, P. R. Tracking Pertussis and Evaluating Control Measures through Enhanced Pertussis Surveillance, Emerging Infections Program, United States. Emerging infectious diseases 21, 1568-1573, doi:10.3201/eid2109.150023 (2015).
10 Poolman, J. T. Shortcomings of pertussis vaccines: why we need a third generation vaccine. Expert review of vaccines 13, 1159-1162, doi:10.1586/14760584.2014.944902 (2014).
11 Dowling, D. J. & Levy, O. Pediatric vaccine adjuvants: Components of the modern vaccinologist's toolbox. The Pediatric infectious disease journal, doi:10.1097/inf.0000000000000893 (2015).
12 Dowling, D. J. & Levy, O. Ontogeny of early life immunity. Trends Immunol 35, 299-310, doi:10.1016/j.it.2014.04.007 (2014).
13 Pollard, A. J., Perrett, K. P. & Beverley, P. C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9, 213-220, doi:nri2494 [pii] 10.1038/nri2494 [doi] (2009).
14 Queenan, A. M. et al. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro. Vaccine 37, 80-89, doi:10.1016/j.vaccine.2018.11.028 (2019).
15 Allen, A. C. & Mills, K. H. Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity. Expert review of vaccines 13, 1253-1264, doi:10.1586/14760584.2014.936391 (2014).
16 Dowling, D. J. & Levy, O. Pediatric Vaccine Adjuvants: Components of the Modern Vaccinologist's Toolbox. Pediatr Infect Dis J 34, 1395-1398, doi:10.1097/INF.0000000000000893 (2015).
17 Nanishi, E., Dowling, D. J. & Levy, O. Toward precision adjuvants: optimizing science and safety. Curr Opin Pediatr 32, 125-138, doi:10.1097/MOP.0000000000000868 (2020).
18 Soni, D. et al. Towards Precision Vaccines: Lessons From the Second International Precision Vaccines Conference. Frontiers in immunology 11, doi:10.3389/fimmu.2020.590373 (2020).
19 van Haren, S. D. et al. In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant. Cytokine 83, 99-109, doi:10.1016/j.cyto.2016.04.001 (2016).
20 Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat Med 19, 1597-1608, doi:nm.3409 [pii] 10.1038/nm.3409 [doi] (2013).
21 Philbin, V. J. et al. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol 130, 195-204 e199, doi:10.1016/j.jaci.2012.02.042 (2012).
22 Ugolini, M. et al. Recognition of microbial viability via TLR8 drives TFH cell differentiation and vaccine responses. Nat Immunol 19, 386-396, doi:10.1038/s41590-018-0068-4 (2018).
23 Browne, E. P. Regulation of B-cell responses by Toll-like receptors. Immunology 136, 370-379, doi:10.1111/j.1365-2567.2012.03587.x (2012).
24 Levy, O. et al. The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J Immunol 177, 1956-1966, doi:10.4049/jimmunol.177.3.1956 (2006).
25 Dowling, D. J. et al. The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes. PLoS One 8, e58164, doi:10.1371/journal.pone.0058164 (2013).
26 Dowling, D. J. et al. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses. J Allergy Clin Immunol 140, 1339-1350, doi:10.1016/j.jaci.2016.12.985 (2017).
27 Holbrook, B. C. et al. An R848 adjuvanted influenza vaccine promotes early activation of B cells in the draining lymph nodes of non-human primate neonates. Immunology, doi:10.1111/imm.12845 (2017).
28 Dowling, D. J. et al. TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth. 2, e91020, doi:10.1172/jci.insight.91020 (2017).
29 Pettengill, M. A. et al. Distinct TLR-mediated cytokine production and immunoglobulin secretion in human newborn naive B cells. Innate immunity, doi:10.1177/1753425916651985 (2016).
30 Misiak, A. et al. Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. Vaccine 35, 5256-5263, doi:10.1016/j.vaccine.2017.08.009 (2017).
31 Soni, D., Bobbala, S., Li, S., Scott, E. A. & Dowling, D. J. The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems. Pediatr Res, 1-9, doi:10.1038/s41390-020-01112-y (2020).
32 Brito, L. A., Malyala, P. & O'Hagan, D. T. Vaccine adjuvant formulations: A pharmaceutical perspective. Semin Immunol 25, 130-145, doi:S1044-5323(13)00037-7 [pii] 10.1016/j.smim.2013.05.007 [doi] (2013).
33 Dowling, D. J. Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants. Immunohorizons 2, 185-197, doi:10.4049/immunohorizons.1700063 (2018).
34 Vasilakos, J. P. & Tomai, M. A. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert review of vaccines 12, 809-819, doi:10.1586/14760584.2013.811208 [doi] (2013).
35 Sauder, D. N., Smith, M. H., Senta-McMillian, T., Soria, I. & Meng, T. C. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrobial agents and chemotherapy 47, 3846-3852 (2003).
36 Szeimies, R. M. et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. The British journal of dermatology 159, 205-210, doi:10.1111/j.1365-2133.2008.08615.x (2008).
37 Dowling, D. J. et al. TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth. JCI Insight 2, e91020, doi:10.1172/jci.insight.91020 (2017).
38 Kasturi, S. P. et al. 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. Sci Immunol 5, doi:10.1126/sciimmunol.abb1025 (2020).
39 Smith, A. J. et al. Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants. Vaccine 34, 4304-4312, doi:10.1016/j.vaccine.2016.06.080 (2016).
40 Gerster, J. F. et al. Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. Journal of medicinal chemistry 48, 3481-3491, doi:10.1021/jm049211v (2005).
41 Evans, J. T. et al. Synthetic Toll-like Receptors 7 and 8 Agonists: Structure-Activity Relationship in the Oxoadenine Series. ACS Omega 4, 15665-15677, doi:10.1021/acsomega.9b02138 (2019).
42 Bazin, H. G. et al. Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity. Bioorg Med Chem Lett 30, 126984, doi:10.1016/j.bmcl.2020.126984 (2020).
43 Pettengill, M. A., van Haren, S. D. & Levy, O. Soluble mediators regulating immunity in early life. Frontiers in immunology 5, 457, doi:10.3389/fimmu.2014.00457 (2014).
44 Mastelic, B. et al. Predictive markers of safety and immunogenicity of adjuvanted vaccines. Biologicals : journal of the International Association of Biological Standardization 41, 458-468, doi:10.1016/j.biologicals.2013.08.006 (2013).
45 Horscroft, N. J., Pryde, D. C. & Bright, H. Antiviral applications of Toll-like receptor agonists. The Journal of antimicrobial chemotherapy 67, 789-801, doi:10.1093/jac/dkr588 (2012).
46 Strominger, N. L., Brady, R., Gullikson, G. & Carpenter, D. O. Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation. Brain Research Bulletin 55, 445-451, doi:https://doi.org/10.1016/S0361-9230(01)00539-1 (2001).
47 Lee, J. et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proceedings of the National Academy of Sciences of the United States of America 100, 6646-6651, doi:10.1073/pnas.0631696100 (2003).
48 Chan, M. et al. Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates. Bioconjugate Chemistry 20, 1194-1200, doi:10.1021/bc900054q (2009).
49 Bazin, H. G., Bess, L. S., Livesay, M. T., Mwakwari, S. C. & Johnson, D. A. Phospholipidation of TLR7/8-active imidazoquinolines using a tandem phosphoramidite method. Tetrahedron Letters 57, 2063-2066, doi:10.1016/j.tetlet.2016.03.091 (2016).
50 Bazin, H. G. a. J., D. A. Pegylated Imidazoquinolines as TLR7 and TLR8 Agonists. (2017).
51 HogenEsch, H., O'Hagan, D. T. & Fox, C. B. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines 3, 51, doi:10.1038/s41541-018-0089-x (2018).
52 Bruschi, M. L. Strategies to modify the drug release from pharmaceutical systems. 1st edition. edn, (Elsevier, 2015).
53 Borriello, F. et al. Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization. Front Immunol 8, 1772, doi:10.3389/fimmu.2017.01772 (2017).
54 Collier, M. A. et al. Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists. Mol Pharm 15, 4933-4946, doi:10.1021/acs.molpharmaceut.8b00579 (2018).
55 Libster, R. & Edwards, K. M. Re-emergence of pertussis: what are the solutions? Expert review of vaccines 11, 1331-1346, doi:10.1586/erv.12.118 (2012).
56 Martinon-Torres, F., Heininger, U., Thomson, A. & Wirsing von Konig, C. H. Controlling pertussis: how can we do it? A focus on immunization. Expert review of vaccines 17, 289-297, doi:10.1080/14760584.2018.1445530 (2018).
57 Liu, L. et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379, 2151-2161, doi:S0140-6736(12)60560-1 [pii] 10.1016/S0140-6736(12)60560-1 [doi] (2012).
58 Wu, T. Y. et al. Rational design of small molecules as vaccine adjuvants. Sci Transl Med 6, 263ra160, doi:10.1126/scitranslmed.3009980 (2014).
59 Miller, S. M. et al. Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice. Frontiers in immunology 11, 406, doi:10.3389/fimmu.2020.00406 (2020).
60 Koff, W. C. et al. Accelerating next-generation vaccine development for global disease prevention. Science (New York, N.Y.) 340, 1232910, doi:10.1126/science.1232910 (2013).
61 Delany, I., Rappuoli, R. & De Gregorio, E. Vaccines for the 21st century. EMBO molecular medicine 6, 708-720, doi:10.1002/emmm.201403876 (2014).
62 Cortez, A. et al. Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide. Journal of medicinal chemistry 59, 5868-5878, doi:10.1021/acs.jmedchem.6b00489 (2016).
63 Buonsanti, C. et al. Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. Scientific reports 6, 29063, doi:10.1038/srep29063 (2016).
64 Gonzalez-Lopez, A. et al. Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine. Clin Immunol 209, 108275, doi:10.1016/j.clim.2019.108275 (2019).
65 Jangra, S. et al. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*. Angew Chem Int Ed Engl 60, 9467-9473, doi:10.1002/anie.202015362 (2021).
66 Mills, K. H., Ross, P. J., Allen, A. C. & Wilk, M. M. Do we need a new vaccine to control the re-emergence of pertussis? Trends Microbiol 22, 49-52, doi:10.1016/j.tim.2013.11.007 (2014).
67 Kapil, P. & Merkel, T. J. Pertussis vaccines and protective immunity. Current opinion in immunology 59, 72-78, doi:10.1016/j.coi.2019.03.006 (2019).
68 Warfel, J. M., Zimmerman, L. I. & Merkel, T. J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proceedings of the National Academy of Sciences of the United States of America 111, 787-792, doi:10.1073/pnas.1314688110 (2014).
69 Kuijpers, A. J. et al. In vivo and in vitro release of lysozyme from cross-linked gelatin hydrogels: a model system for the delivery of antibacterial proteins from prosthetic heart valves. J Control Release 67, 323-336, doi:10.1016/s0168-3659(00)00221-2 (2000).
70 Northrup, L. et al. Co-delivery of autoantigen and dexamethasone in incomplete Freund's adjuvant ameliorates experimental autoimmune encephalomyelitis. J Control Release 266, 156-165, doi:10.1016/j.jconrel.2017.09.034 (2017).
71 Zhang, Y. et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J 12, 263-271, doi:10.1208/s12248-010-9185-1 (2010).
72 Raeven, R. H. M. et al. Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination. Mucosal Immunol 11, 1009, doi:10.1038/mi.2017.110 (2018).
73 Ganapathi, L. et al. The Imidazoquinoline Toll-Like Receptor-7/8 Agonist Hybrid-2 Potently Induces Cytokine Production by Human Newborn and Adult Leukocytes. PLoS One 10, e0134640, doi:10.1371/journal.pone.0134640 (2015).
74 Smith, A. J. et al. Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants. Vaccine 34, 4304-4312, doi:http://dx.doi.org/10.1016/j.vaccine.2016.06.080 (2016).
75 Bazin, H. G. et al. Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives. Bioorganic & Medicinal Chemistry Letters 25, 1318-1323, doi:http://dx.doi.org/10.1016/j.bmcl.2015.01.037 (2015).